Global epigenetic profiling in bladder cancer

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J. Clin.60(5),277–300 (2010).
  MedlineGoogle Scholar
• 2  Avritscher EB, Cooksley CD, Grossman HB et al.: Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology68(3),549–553 (2006).
  MedlineGoogle Scholar
• 3  Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA: The economic consequences of prostate and bladder cancer in the UK. BJU Int.95(1),59–63 (2005).
  MedlineGoogle Scholar
• 4  PJ Goebell , Knowles MA: Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol. Oncol.28(4),409–428 (2010).▪ Describes and summarizes genetic alterations reported in bladder cancer in the current two-pathway model.
  MedlineGoogle Scholar
• 5  Catto JW, Rosario DJ: The road to cystectomy: who, when and why? EAU update series. Eur. Urol.3(4),171–179 (2005).
  Google Scholar
• 6  Catto JW, Yates DR, Rehman I et al.: Behavior of urothelial carcinoma with respect to anatomical location. J. Urol.177(5),1715–1720 (2007).
  Medline CASGoogle Scholar
• 7  Stein JP, Lieskovsky G, Cote R et al.: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3),666–675 (2001).
  Medline CASGoogle Scholar
• 8  KnowlesMA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis27(3),361–373 (2006).
  Medline CASGoogle Scholar
• 9  Dhawan D, Hamdy FC, Rehman I et al.: Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J. Pathol.209(3),336–343 (2006).
  Medline CASGoogle Scholar
• 10  Dyrskjot L, Kruhoffer M, Thykjaer T et al.: Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res.64(11),4040–4048 (2004).
  Medline CASGoogle Scholar
• 11  van Oers JM, Zwarthoff EC, Rehman I et al.: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumors. Eur. Urol.55(3),650–657 (2009).
  Medline CASGoogle Scholar
• 12  Jebar AH, Hurst CD, Tomlinson DC et al.: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene24(33),5218–5225 (2005).
  Medline CASGoogle Scholar
• 13  Zhang ZT, Pak J, Huang HY et al.: Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene20(16),1973–1980 (2001).
  Medline CASGoogle Scholar
• 14  Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR: Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res.59(14),3512–3517 (1999).
  Medline CASGoogle Scholar
• 15  Spruck CH, Ohneseit PF, Gonzalez-Zulueta M et al.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res.54(3),784–788 (1994).
  Medline CASGoogle Scholar
• 16  Catto JW, Miah S, Owen HC et al.: Distinct miRNA alterations characterize high- and low-grade bladder cancer. Cancer Res.69(21),8472–8481 (2009).▪▪ Reports that altered miRNA expression occurs in a tumor phenotype-specific manner and can predict disease progression. Examines the role of DNA methylation in miRNA downregulation.
  Medline CASGoogle Scholar
• 17  Yates DR, Rehman I, Abbod MF et al.: Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res.13(7),2046–2053 (2007).▪ Describes aberrant DNA methylation as reliable predictor of tumor progression in bladder cancer.
  Medline CASGoogle Scholar
• 18  Dyrskjot L, Ostenfeld MS, Bramsen JB et al.: Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res.69(11),4851–4860 (2009).▪▪ Reports that altered miRNA expression occurs in a tumor phenotype-specific manner and can predict disease progression.
  Medline CASGoogle Scholar
• 19  Serizawa RR, Ralfkiaer U, Steven K et al.: Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J. Cancer doi: 10.1002/ijc.25651 (2010) (Epub ahead of print).
  Google Scholar
• 20  Weisenberger DJ, Siegmund KD, Campan M et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet.38(7),787–793 (2006).
  Medline CASGoogle Scholar
• 21  Ordway JM, Williams K, Curran T: Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene23(21),3737–3748 (2004).
  Medline CASGoogle Scholar
• 22  Watt F, Molloy PL: Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev.2(9),1136–1143 (1988).
  Medline CASGoogle Scholar
• 23  Nan X, Campoy FJ, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell88(4),471–481 (1997).
  Medline CASGoogle Scholar
• 24  Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science300(5618),455 (2003).
  Medline CASGoogle Scholar
• 25  Gaudet F, Hodgson JG, Eden A et al.: Induction of tumors in mice by genomic hypomethylation. Science300(5618),489–492 (2003).
  Medline CASGoogle Scholar
• 26  Estecio MR, Gharibyan V, Shen L et al.: LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS ONE2(5),e399 (2007).
  MedlineGoogle Scholar
• 27  Prusty BK, zur Hausen H, Schmidt R, Kimmel R, de Villiers EM: Transcription of HERV-E and HERV-E-related sequences in malignant and non-malignant human haematopoietic cells. Virology382(1),37–45 (2008).
  Medline CASGoogle Scholar
• 28  Lamprecht B, Walter K, Kreher S et al.: Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat. Med.16(5),571–579 (2010).
  Medline CASGoogle Scholar
• 29  Wolff EM, Byun HM, Han HF et al.: Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet.6(4),e1000917 (2010).▪ Demonstrates that hypomethylation of retrotransposons causes altered gene expression in bladder cancer.
  MedlineGoogle Scholar
• 30  Buscher K, Hahn S, Hofmann M et al.: Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res.16(3),223–234 (2006).
  MedlineGoogle Scholar
• 31  Ishida T, Obata Y, Ohara N et al.: Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity. Cancer Immun.8,15 (2008).
  MedlineGoogle Scholar
• 32  Wang-Johanning F, Liu J, Rycaj K et al.: Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int. J. Cancer.120(1),81–90 (2007).
  Medline CASGoogle Scholar
• 33  Dudziec E, Miah S, Choudhry H et al.: Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin. Cancer Res. (2010) (Epub ahead of print).
  Google Scholar
• 34  Marsit CJ, Houseman EA, Christensen BC et al.: Identification of methylated genes associated with aggressive bladder cancer. PLoS ONE5(8),e12334 (2010).
  MedlineGoogle Scholar
• 35  Wolff EM, Chihara Y, Pan F et al.: Unique DNA methylation patterns distinguish superficial and invasive bladder cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res.70(20),8169–8178 (2010).▪▪ Desribes unique DNA methylation patterns in different types of tumors and highlights changes occuring in normal bladders with cancers.
  Medline CASGoogle Scholar
• 36  Catto JW, Hartmann A, Stoehr R et al.: Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J. Urol.175(6),2323–2330 (2006).
  Medline CASGoogle Scholar
• 37  Catto JW, Azzouzi AR, Rehman I et al.: Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol.23(13),2903–2910 (2005).
  Medline CASGoogle Scholar
• 38  Cebrian V, Alvarez M, Aleman A et al.: Discovery of myopodin methylation in bladder cancer. J. Pathol.216(1),111–119 (2008).
  Medline CASGoogle Scholar
• 39  Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG: Methylation patterns of the E-cadherin 5´ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J. Biol Chem.275(4),2727–2732 (2000).
  Medline CASGoogle Scholar
• 40  Byun HM, Wong HL, Birnstein EA et al.: Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res.67(22),10753–10758 (2007).
  Medline CASGoogle Scholar
• 41  Wilhelm CS, Kelsey KT, Butler R et al.: Implications of LINE1 methylation for bladder cancer risk in women. Clin. Cancer Res.16(5),1682–1689 (2010).
  Medline CASGoogle Scholar
• 42  Choi SH, Worswick S, Byun HM et al.: Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J. Cancer.125(3),723–729 (2009).
  Medline CASGoogle Scholar
• 43  Moore LE, Pfeiffer RM, Poscablo C et al.: Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case–control study. Lancet Oncol.9(4),359–366 (2008).
  Medline CASGoogle Scholar
• 44  Kouzarides T: Chromatin modifications and their function. Cell.128(4),693–705 (2007).
  Medline CASGoogle Scholar
• 45  Nguyen CT, Weisenberger DJ, Velicescu M et al.: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2´-deoxycytidine. Cancer Res.62(22),6456–6461 (2002).
  Medline CASGoogle Scholar
• 46  Wiencke JK, Zheng S, Morrison Z, Yeh RF: Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene27(17),2412–2421 (2008).
  Medline CASGoogle Scholar
• 47  Vakoc CR, Mandat SA, Olenchock BA, Blobel GA: Histone H3 lysine 9 methylation and HP1γ are associated with transcription elongation through mammalian chromatin. Mol. Cell19(3),381–391 (2005).
  Medline CASGoogle Scholar
• 48  Squazzo SL, O’Geen H, Komashko VM et al.: Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res.16(7),890–900 (2006).
  Medline CASGoogle Scholar
• 49  Kondo Y, Shen L, Cheng AS et al.: Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet.40(6),741–750 (2008).
  Medline CASGoogle Scholar
• 50  Weikert S, Christoph F, Kollermann J et al.: Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. Med.16(2),349–353 (2005).
  Medline CASGoogle Scholar
• 51  Varambally S, Dhanasekaran SM, Zhou M et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature419(6907),624–629 (2002).
  Medline CASGoogle Scholar
• 52  Kleer CG, Cao Q, Varambally S et al.: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA100(20),11606–11611 (2003).
  Medline CASGoogle Scholar
• 53  Cao Q, Yu J, Dhanasekaran SM et al.: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene27(58),7274–7284 (2008).
  Medline CASGoogle Scholar
• 54  Ou JN, Torrisani J, Unterberger A et al.: Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem. Pharmacol.73(9),1297–1307 (2007).
  Medline CASGoogle Scholar
• 55  Sachs MD, Ramamurthy M, Poel H et al.: Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther.11(7),477–486 (2004).
  Medline CASGoogle Scholar
• 56  Selbach M, Schwanhausser B, Thierfelder N et al.: Widespread changes in protein synthesis induced by microRNAs. Nature455(7209),58–63 (2008).
  Medline CASGoogle Scholar
• 57  Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet.10(10),704–714 (2009).
  Medline CASGoogle Scholar
• 58  Gottardo F, Liu CG, Ferracin M et al.: Micro-RNA profiling in kidney and bladder cancers. Urol. Oncol.25(5),387–392 (2007).
  Medline CASGoogle Scholar
• 59  Valadi H, Ekstrom K, Bossios A et al.: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol.9(6),654–659 (2007).
  Medline CASGoogle Scholar
• 60  Hanke M, Hoefig K, Merz H et al.: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol.28(6),655–661 (2010).▪ Describes the upregulation of urinary miRNAs as potential biomarker to discriminate patients with cancer.
  Medline CASGoogle Scholar
• 61  Saito Y, Liang G, Egger G et al.: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell9(6),435–443 (2006).▪▪ Fisrt report demonstrating epigenetic regulation of miRNA in bladder cancer.
  Medline CASGoogle Scholar
• 62  Saito Y, Friedman JM, Chihara Y et al.: Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem. Biophys. Res. Commun.379(3),726–731 (2009).
  Medline CASGoogle Scholar
• 63  Wiklund ED, Bramsen JB, Hulf T et al.: Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer (2010) (Epub ahead of print).
  Google Scholar
• 64  Fabbri M, Garzon R, Cimmino A et al.: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B Proc. Natl Acad. Sci. USA104(40),15805–15810 (2007).
  Medline CASGoogle Scholar
• 65  Friedman JM, Liang G, Liu CC et al.: The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res.69(6),2623–2629 (2009).
  Medline CASGoogle Scholar
• 66  Brunk BP, Goldhamer DJ, Emerson CC Jr: Regulated demethylation of the myoD distal enhancer during skeletal myogenesis. Dev. Biol.177(2),490–503 (1996).
  Medline CASGoogle Scholar
• 67  Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al.: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol.10(3),223–232 (2009).
  Medline CASGoogle Scholar
• 68  Gore SD, Baylin S, Sugar E et al.: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res.66(12),6361–6369 (2006).
  Medline CASGoogle Scholar
• 69  Kim MS, Blake M, Baek JH et al.: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res.63(21),7291–7300 (2003).
  Medline CASGoogle Scholar
• 70  Hauswald S, Duque-Afonso J, Wagner MM et al.: Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin. Cancer Res.15(11),3705–3715 (2009).
  Medline CASGoogle Scholar
• 71  Cheng JC, Weisenberger DJ, Gonzales FA et al.: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell Biol.24(3),1270–1278 (2004).
  Medline CASGoogle Scholar
• 72  Christoph F, Kempkensteffen C, Weikert S et al.: Methylation of tumor suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br. J. Cancer.95(12),1701–1707 (2006).
  Medline CASGoogle Scholar
• 73  Aleman A, Cebrian V, Alvarez M et al.: Identification of PMF1 methylation in association with bladder cancer progression. Clin. Cancer Res.14(24),8236–8243 (2008).
  Medline CASGoogle Scholar
• 74  Huang Y, Stewart TM, Wu Y et al.: Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin. Cancer Res.15(23),7217–7228 (2009).
  Medline CASGoogle Scholar
• 75  Lakshmikuttyamma A, Scott SA, DeCoteau JF, Geyer CR: Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene29(4),576–588 (2010).
  Medline CASGoogle Scholar
• 76  Tan J, Yang X, Zhuang L et al.: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev.21(9),1050–1063 (2007).
  Medline CASGoogle Scholar
• 77  Gupta R, Nagarajan A, Wajapeyee N: Advances in genome-wide DNA methylation analysis. Biotechniques49(4),iii–xi (2010).
  Medline CASGoogle Scholar
• 78  Pomraning KR, Smith KM, Freitag M: Genome-wide high throughput analysis of DNA methylation in eukaryotes. Methods47(3),142–150 (2009).
  Medline CASGoogle Scholar
• 79  Park PJ: ChIP-seq: advantages and challenges of a maturing technology. Nat. Rev. Genet.10(10),669–680 (2009).
  Medline CASGoogle Scholar
• 80  Irizarry RA, Ladd-Acosta C, Wen B et al.: The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet.41(2),178–186 (2009).
  Medline CASGoogle Scholar
• 81  Lister R, Pelizzola M, Dowen RH et al.: Human DNA methylomes at base resolution show widespread epigenomic differences. Nature462(7271),315–322 (2009).
  Medline CASGoogle Scholar
• 82  Kim WJ, Kim EJ, Jeong P et al.: RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res.65(20),9347–9354 (2005).
  Medline CASGoogle Scholar
• 83  Dominguez G, Carballido J, Silva J et al.: p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin. Cancer Res.8(4),980–985 (2002).
  Medline CASGoogle Scholar
• 84  Chan MW, Chan LW, Tang NL et al.: Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res.8(2),464–470 (2002).
  Medline CASGoogle Scholar
• 85  Hoque MO, Begum S, Topaloglu O et al.: Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst.98(14),996–1004 (2006).
  Medline CASGoogle Scholar
• 86  Friedrich MG, Chandrasoma S, Siegmund KD et al.: Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur. J. Cancer.41(17),2769–2778 (2005).
  Medline CASGoogle Scholar
• 87  Ellinger J, El Kassem N, Heukamp LC et al.: Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol.179(1),346–352 (2008).
  Medline CASGoogle Scholar
• 88  Maruyama R, Toyooka S, Toyooka KO et al.: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res.61(24),8659–8663 (2001).
  Medline CASGoogle Scholar
• 89  Abbosh PH, Wang M, Eble JN et al.: Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. Mod. Pathol.21(3),355–362 (2008).
  Medline CASGoogle Scholar
• 90  Yang J, Xu Z, Li J et al.: XPC epigenetic silence coupled with p53 alteration has a significant impact on bladder cancer outcome. J. Urol.184(1),336–343 (2010).
  Medline CASGoogle Scholar
• 91  Friedrich MG, Weisenberger DJ, Cheng JC et al.: Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res.10(22),7457–7465 (2004).
  Medline CASGoogle Scholar
• 92  Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT: Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis28(8),1745–1751 (2007).
  Medline CASGoogle Scholar
• 93  Sathyanarayana UG, Maruyama R, Padar A et al.: Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res.64(4),1425–1430 (2004).
  Medline CASGoogle Scholar
• 94  Aleman A, Adrien L, Lopez-Serra L et al.: Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br. J. Cancer98(2),466–473 (2008).
  Medline CASGoogle Scholar
• 95  Tada Y, Wada M, Taguchi K et al.: The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res.62(14),4048–4053 (2002).
  Medline CASGoogle Scholar
• 96  Chiyomaru T, Enokida H, Kawakami K et al.: Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol. Oncol. (2010) (Epub ahead of print).
  Google Scholar
• 97  Cao Y, Yu SL, Wang Y et al.: MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24. Tumor Biol.32(1),179–188 (2010).
  MedlineGoogle Scholar
• 98  Ichimi T, Enokida H, Okuno Y et al.: Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J. Cancer.125(2),345–352 (2009).
  Medline CASGoogle Scholar
• 99  Lodygin D, Tarasov V, Epanchintsev A et al.: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle7(16),2591–2600 (2008).
  Medline CASGoogle Scholar
• 100  Huang L, Luo J, Cai Q et al.: MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int. J. Cancer doi: 10.1002/ijc.25509 (2010) (Epub ahead of print).
  Google Scholar
• 101  Chiyomaru T, Enokida H, Tatarano S et al.: miR-145 and miR-133a function as tumor suppressors and directly regulate FSCN1 expression in bladder cancer. Br. J. Cancer102(5),883–891 (2010).
  Medline CASGoogle Scholar
• 102  Ostenfeld MS, Bramsen JB, Lamy P et al.: miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene29(7),1073–1084 (2010).
  Medline CASGoogle Scholar
• 103  Adam L, Zhong M, Choi W et al.: miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res.15(16),5060–5072 (2009).
  Medline CASGoogle Scholar
• 104  Lu Q, Lu C, Zhou GP et al.: MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol. Oncol. (6),635–641 (2009).
  MedlineGoogle Scholar
• 201  Contains the reference sequence and working draft assemblies for a large collection of genomes http://genome.ucsc.edu
  Google Scholar